Samsung Biologics Secures $668 Mn Manufacturing Deals with European Pharma Giant
Running through December 2031, these agreements bolster Samsung Biologics’ position as a critical player in global biopharma manufacturing.
Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced manufacturing contracts worth $668 million with an undisclosed Europe-based pharmaceutical company.
Running through December 2031, these agreements bolster Samsung Biologics’ position as a critical player in global biopharma manufacturing.
This latest deal adds to Samsung Biologics’ cumulative contract value for 2024, exceeding $4 billion.
John Rim, president and CEO of Samsung Biologics, commented, “We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients. As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest quality services at every stage and deepen our trusted partnerships.”
The company is poised to enhance its service offerings by adding antibody-drug conjugate (ADC) capabilities, with a dedicated facility expected to be operational by year-end.
This expansion aligns with the growing demand for specialized biopharmaceutical manufacturing and complements Samsung Biologics’ expertise in antibody engineering and biologics production.
Samsung Biologics also announced the development of Bio Campus II, which will include Plant 5, scheduled to become operational in April 2025. These initiatives signify the company's commitment to addressing the evolving needs of clients in delivering innovative therapies.
Global Reach & Expansion
With partnerships established with 17 of the world’s top 20 pharmaceutical companies, Samsung Biologics continues to solidify its presence in the United States, Asia, and Europe. The firm has demonstrated a proactive approach to securing long-term collaborations and supporting clients in advancing biopharmaceutical solutions globally.
Rim highlighted the company’s strategy, saying, “As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies.”
Samsung Biologics’ integrated CDMO services include cell line development, aseptic fill/finish processes, and laboratory testing, ensuring seamless support for clients at every stage of biopharmaceutical product development.
